Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
Abstract: The present invention relates to a composition for muscle function improvement or exercise ability enhancement, the composition including kirenol, a Siegesbeckia herba extract, or a fraction of the Siegesbeckia herba extract as an active ingredient. Kirenol, the Siegesbeckia herba extract containing kirenol, or the Siegesbeckia herba extract fraction according to the present invention has an excellent effect of increasing muscle mass by increasing the protein expression of p-mTOR, which is a major gene concerned with muscle functions. Also, kirenol, the Siegesbeckia herba extract containing kirenol, or the Siegesbeckia herba extract fraction according to the present invention has an effect of remarkably enhancing exercise ability by increasing the protein expression of PGC-1?, which is a major gene concerned with exercise ability. In addition, the present invention is a natural product, and thus is safe for use without side effects and can be used as a medicine or food.
Type:
Grant
Filed:
December 27, 2016
Date of Patent:
December 17, 2019
Assignee:
AAT Costech Co., Ltd.
Inventors:
Jae-Kwan Hwang, Mi-Bo Kim, Chang Hee Kim
Abstract: Cysteine compositions comprising less than about 400 ?g/L of aluminum. For example, solutions of cysteine comprising a pharmaceutically acceptable solvent, cysteine, and less than about 145 ?g/L of aluminum, wherein the solution is devoid of visible particulate matter. Cysteine compositions described herein may be suitable for injection. For example, disclosed cysteine solutions may be provided intravenously to meet amino acid nutritional requirement in individuals receiving total parenteral nutrition. Also provided are processes for preparing cysteine compositions, and methods for providing cysteine to individuals in need thereof.
Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
Abstract: The present invention relates to a pharmaceutical composition comprising an inclusion complex of amorphous lenalidomide, or a pharmaceutically acceptable salt thereof, in non-substituted ?-cyclodextrin and one or more pharmaceutically acceptable excipients. The invention further relates to the use of said composition as a medicament, particularly in the treatment of in the treatment of multiple myeloma and myelodysplastic syndromes.
Type:
Grant
Filed:
December 16, 2015
Date of Patent:
November 12, 2019
Assignee:
Synthon B.V.
Inventors:
Rolf Keltjens, Jacobus Theodorus Henricus Van Eupen, Deepak Murpani, Marta Vivancos Martinez, Lisardo Alvarez Fernandez, Luis Nogueiras Nieto
Abstract: A novel omega-3 fatty acid/lipid based nutraceutical composition and a method of optimizing said omega-3 fatty acid/lipid based nutraceutical composition. The nutraceutical composition and method is based on the insight that different forms of high omega-3 fatty acid lipids (e.g. triglyceride form, ethyl ester form, free fatty acid form, phospholipid form) have different molecular modes and levels of action. Specifically the phospholipid form is likely more effective at promoting membrane fluidity and permeability, while the free fatty acid form is likely more effective at regulating cell receptors, such as the PPARa receptors, that are responsible for various metabolic effects including lipid metabolism. The desirability of producing omega-3 compositions that may act synergistically and thus more robustly to improve health and to some extent mimic markers of life extension such as shown by caloric restriction, along with specific optimization methods, markers, and compositions are taught.
Abstract: The present invention provides an agent for treating and/or preventing adult T cell leukemia/lymphoma containing a compound having a specific chemical structure or a pharmaceutically acceptable salt thereof. Specifically, the present invention provides an agent for treating and/or preventing adult T cell leukemia/lymphoma containing, as an active ingredient, 7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide or a pharmaceutically acceptable salt thereof, or 7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
July 29, 2016
Date of Patent:
October 8, 2019
Assignees:
DAIICHI SANKYO COMPANY, LIMITED, THE UNIVERSITY OF TOKYO
Abstract: A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously over a prolonged time period is disclosed. In certain embodiments, the dose is intravenously administered in a time period from about 10 minutes to about 3 hours, preferably from about 10 minutes to about 30 minutes. In other embodiments, intravenous doses are administered at suitable time intervals over a time period from about 3 hours to 48 hours.
Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
Abstract: Compounds having the following formula (E): or a pharmaceutically acceptable salt thereof, wherein R, R?, R?, X and n are as defined herein are provided. Methods comprising use of such compounds for the treatment of neurologic disorders, such as pantothenate kinase-associated neurodegeneration, and pharmaceutical compositions containing such compounds, and their use in treatment of neurologic disorders are also provided.
Type:
Grant
Filed:
January 5, 2018
Date of Patent:
September 10, 2019
Assignee:
Retrophin, Inc.
Inventors:
Andrew Vaino, Marek Biestek, Martin Shkreli
Abstract: The use of tapentadol in the treatment of pain and/or pain chronification in a subject suffering from pain chronification and/or in the treatment of pain and inhibition of pain chronification in a subject suffering from pain and at risk of pain chronification, as well as the use of tapentadol for the treatment or inhibition of migraine.
Type:
Grant
Filed:
August 22, 2016
Date of Patent:
September 3, 2019
Assignee:
GRUENENTHAL GMBH
Inventors:
Klaus Schiene, Ilona Steigerwald, Michel Hamon, Johannes Schneider, Silvia Reinartz, Ulrich Jahnel, Thomas Tzschentke
Abstract: The present invention relates to methods and compositions for determining the likelihood that a subject suffering from a cancer will benefit from treatment with a MEK inhibitor. It also relates to methods of treatment based on such determination. The invention is based, at least in part, on the discoveries that DDX43 mRNA and protein are expressed at high levels in biopsies from “non-responder” UM patients and that selumetinib-resistant cell lines showed high DDX43 expression which correlated with increased expression and activity of RAS. It was found that KRAS and HRAS but not NRAS, mediated expression of pERK and pAKT, bypassing oncogenic GNAQ. The invention is further based on the discovery that selumetinib-resistant cells became sensitive to AKT inhibition, suggesting alternative strategies for the treatment of cancer patients with acquired resistance to MEK inhibitors.
Type:
Grant
Filed:
March 4, 2016
Date of Patent:
September 3, 2019
Assignee:
Memorial Sloan-Kettering Cancer Center
Inventors:
Grazia Ambrosini, Raya Khanin, Richard Carvajal, Gary K. Schwartz
Abstract: The present invention provides a method for diagnosing or determining the risk of developing Alzheimer's disease and for treating Alzheimer's disease with S-equol. An aspect of the present invention includes the use of a direct mitochondrial target engagement biomarker to diagnose or assess the risk of developing Alzheimer's disease. Another aspect of the present invention includes the use of a pharmaceutically effective amount of S-equol to treat or prevent Alzheimer's disease in a subject diagnosed with or determined to be at risk of developing Alzheimer's disease.
Abstract: The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufacture of a medicament for the treatment of a protozoan infection in a subject. The invention further provides a medical device when used in a method of treating or preventing a protozoan infection in a subject and to a medical device comprising the composition of the invention.
Type:
Grant
Filed:
August 28, 2015
Date of Patent:
August 27, 2019
Assignee:
Neoculi Pty Ltd.
Inventors:
Stephen Page, Andrew Stevens, Adam McCluskey, Martine Keenan, Rebecca Abraham
Abstract: The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of IL-17 and TNF-?, which are inflammatory cytokines, increases the activity of regulatory T cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases. Accordingly, the biguanide-based derivative compound can be usefully used as an immunosuppressant or a pharmaceutical composition capable of preventing or treating various immune diseases, such as autoimmune diseases, inflammatory diseases, and transplant rejection, caused by the dysregulation of immune responses.
Type:
Grant
Filed:
August 25, 2014
Date of Patent:
August 6, 2019
Assignee:
The Catholic University of Korea Industry-Academic Cooperation Foundation
Inventors:
Mi-La Cho, Chul-Woo Yang, Dong-Yun Shin, Min-Jung Park, Seon-Yeong Lee, Sung-Hee Lee, Eun-Ji Yang, Hye-Jin Son, Eun-Kyung Kim, Jae-Kyung Kim
Abstract: The present invention relates to methods of treating or preventing cancer in a subject in need thereof comprising administering a therapeutically effective amount of a compound of the invention.
Type:
Grant
Filed:
April 11, 2017
Date of Patent:
August 6, 2019
Assignee:
Intercept Pharmaceuticals, Inc.
Inventors:
Antonio Moschetta, Jesus Maria Banales Asurmedi, Luis Bujanda Fernández de Pierola, María Jesús Perugorria Montiel, Oihane Erice Azparren
Abstract: Provided is an antihypertensive agent that is safe and has a mild effect. An antihypertensive agent comprising S-1-propenylcysteine or a salt thereof as an active ingredient.
Abstract: This invention is directed to prostaglandin E2 receptor 4 (EP4) antagonists useful in the treatment of nonalcoholic steatohepatitis (NASH)-associated liver cancer in a human or animal. The method comprises administering one or more of Compound A, Compound B or Compound C, or pharmaceutically acceptable salts thereof, as the EP4 antagonist(s). The method may include a pharmaceutical composition comprising the EP4 antagonist, and may include one or more other active agents and/or therapies.
Abstract: This disclosure relates to progesterone derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation resulting from traumatic brain injury or stroke.
Type:
Grant
Filed:
November 4, 2015
Date of Patent:
July 2, 2019
Assignee:
Emory University
Inventors:
David B Guthrie, Mark A Lockwood, Dennis C. Liotta, Michael G Natchus, Donald G. Stein, Iqbal Sayeed
Abstract: The present invention relates to a pharmaceutical composition comprising a compound of formula (1), (2) or (3) as defined in the specification for the prevention or treatment of diseases associated with oxidative stress, mitochondria dysfunction, hypoxic injury, necrosis and/or ischemic reperfusion injury, and a cosmetic composition comprising an indole compound having an antioxidant effect.
Type:
Grant
Filed:
February 24, 2017
Date of Patent:
June 18, 2019
Assignee:
LG CHEM, LTD.
Inventors:
Soon Ha Kim, Hyoung Jin Kim, Heui Sul Park, Seon Yeong Gu, Hyo Shin Kwak, Du Hee Park, Hyo Soo Kim, Hyun Jai Cho, Ji Hyun Kim, Ju Young Kim, Kwang Min Park